Acquired Amegakaryocytic Thrombocytopenic Purpura: A Review of Therapeutic Options.
Hematol Oncol Stem Cell Ther
; 16(3): 291-302, 2023 Apr 04.
Article
in En
| MEDLINE
| ID: mdl-37023223
ABSTRACT
Acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare bone marrow disorder characterized by either a marked decrease or a complete absence of megakaryocytes with the preservation of all other cell lines. To date, more than 60 cases of AATP have been reported in the literature. Due to the rarity of this disease, no standard treatment guidelines have been established, and therapy is based on a handful of case studies and expert opinions. Herein, we provide a comprehensive review of currently utilized therapeutic options for AATP.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Purpura, Thrombocytopenic
/
Bone Marrow Diseases
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Hematol Oncol Stem Cell Ther
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2023
Document type:
Article
Affiliation country:
United States